Photodynamic therapy with 3-(1′-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study

Background The purpose of this study was for us to report results regarding the safety of 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses. Methods A single‐institution, phase Ib, o...

Full description

Saved in:
Bibliographic Details
Published inHead & neck Vol. 38; no. S1; pp. E377 - E383
Main Authors Shafirstein, Gal, Rigual, Nestor R., Arshad, Hassan, Cooper, Michele T., Bellnier, David A., Wilding, Gregory, Tan, Wei, Merzianu, Mihai, Henderson, Barbara W.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.04.2016
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background The purpose of this study was for us to report results regarding the safety of 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses. Methods A single‐institution, phase Ib, open label, noncomparative study of HPPH‐PDT in patients with high‐risk dysplasia, carcinoma in situ, and T1 squamous cell carcinoma (SCC) of the larynx. The primary outcomes were safety and maximum tolerated dose (MTD), and the secondary outcome was response. Results Twenty‐nine patients and 30 lesions were treated. The most common adverse event (AE) was transient hoarseness of voice. Severe edema, requiring tracheostomy, was the most serious AE, which occurred in 2 patients within several hours of therapy. The MTD was 100 J/cm2. Patients with T1 SCC seemed to have good complete response rate (82%) to HPPH‐PDT at MTD. Conclusion HPPH‐PDT can be safely used to treat early‐stage laryngeal cancer, with potential efficacy. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 38: E377–E383, 2016
Bibliography:ark:/67375/WNG-G3BWV5FH-9
istex:BF132EA41569A25FD17336375B93C5C65B6DA12B
ArticleID:HED24003
National Cancer Institute - No. PO1CA55791
Roswell Park Cancer Institute - No. P30CA16056
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.24003